Results 201 to 210 of about 32,100 (296)

Optimizing safety and efficacy of asparaginase and blinatumomab therapy in frontline acute lymphoblastic leukemia regimens in diverse health care settings—international expert consensus

Cancer, Volume 132, Issue 16, 15 August 2026.
ABSTRACT Frontline blinatumomab combined with chemotherapy has resulted in improved outcomes in both pediatric and adult patients with acute lymphoblastic leukemia and is considered the new cornerstone of acute lymphoblastic leukemia treatment. The role of asparaginase in this new landscape of acute lymphoblastic leukemia treatment was extensively ...
Daniel J. DeAngelo, Anna Avagyan, Jeanine Alfaro, Valentino Conter, Maria L. de Martino Lee, Łukasz Hutnik, Miriam Hwang, Hiroto Inaba, Atsushi Manabe, Jae H. Park, Rob Pieters, Carmelo Rizzari, Vaskar Saha, David T. Teachey, Inge M. van der Sluis, Scott C. Howard   +15 more
wiley   +1 more source

The trajectory of fatigue over time in breast cancer patients treated with chemotherapy: exploring the effect of anthracycline-based chemotherapy. [PDF]

Breast
Kastelein A, Kervezee L, Mink van der Molen DR, Evers DJ, van der Pol CC, Doeksen A, Chavannes NH, Gelderblom H, Neefjes J, Verkooijen HM, May AM.   +10 more
europepmc   +1 more source

Doxorubicin‐Induced Cytotoxicity in Adipose‐Derived Stem Cells Is Associated With Altered SAPK/JNK Signaling

The FASEB Journal, Volume 40, Issue 15, 15 August 2026.
This study investigated the effects of clinically relevant concentrations of doxorubicin (Dox; 5 μM), commonly used in anticancer therapy, on adipose‐derived stem cells (ADSCs). Dox induced ADSC dysfunction, characterized by reduced mitochondrial activity, apoptosis, oxidative stress, premature senescence, cytoskeletal alterations, and cell cycle ...
Aleksandra Skubis‐Sikora, Kinga Pogoda‐Mieszczak, Bartosz Sikora, Edyta Bogunia, Aleksandra Bryzek, Piotr Czekaj   +5 more
wiley   +1 more source

New-Onset Atrial Fibrillation as an Early Marker of Anthracycline-Associated Cardiotoxicity and Mortality: A Retrospective Study. [PDF]

Cureus
Homeniuk A, Karthikeyan G, Atrash A.
europepmc   +1 more source

Correction for Abels et al., Manipulating anthracyclines for deeper tissue penetration and implications for glycolytic tissues. [PDF]

Proc Natl Acad Sci U S A
europepmc   +1 more source

Caught in the crossfire: cardiac complications of cancer therapy. [PDF]

J Clin Invest
Guerra G, Mergiotti M, Ardehali H, Hirsch E, Ghigo A.   +4 more
europepmc   +1 more source

Low‐Dose Antiangiogenic Therapy With Different Chemotherapy Backbones Among Patients With Heavily Pretreated Metastatic Breast Cancer

Cancer Innovation, Volume 5, Issue 4, August 2026.
Antiangiogenic‐based regimens demonstrated superior efficacy compared to chemotherapy alone in heavily pretreated MBC patients, with manageable AEs. ABSTRACT Background The prognosis for metastatic breast cancer (MBC) remains poor, and treatment options are limited for patients with heavily pretreated disease. Although antiangiogenic agents may provide
Yuanyi Wang, Yalong Qi, Cheng Zeng, Ruixia Song, Yuhan Wei, Haili Qian, Fei Ma   +6 more
wiley   +1 more source

CT-derived myosteatosis for baseline risk stratification of cardiotoxicity in patients with diffuse large B-cell lymphoma receiving anthracyclines. [PDF]

BMC Med Imaging
Shen H, Tu C, Xie Y, Xu Q, Deng Y, Zhang J, Guo D.   +6 more
europepmc   +1 more source

Clinical Advances in Breast Cancer: A Comprehensive Overview of Full‐Course Disease Management

Cancer Innovation, Volume 5, Issue 4, August 2026.
This review provides a comprehensive overview of clinical advances in breast cancer, highlighting subtype‐specific therapeutic paradigms. It underscores the full‐cycle integration of innovative therapies, as well as the growing role of biomarker‐guided strategies in advancing precision medicine.
Xuenan Peng, Yujing Tan, Fei Ma
wiley   +1 more source

Sodium-Glucose Cotransporter-2 Inhibitors in Anthracycline-Treated Cancer Patients: A Narrative Review of Emerging Cardioprotective Evidence. [PDF]

Cureus
Nabhan E, Vana AP, Khouri R, Naoum Nehme E, Poulos N.   +4 more
europepmc   +1 more source